Efficacy of NY-198 against experimental Legionnaires disease.
The in vitro and in vivo effects of NY-198 against Legionella pneumophila were compared with those of ciprofloxacin. The MIC of NY-198 against 15 standard reference strains of Legionella of various species, between 0.03 and 0.125 micrograms/ml, was the same as that of ciprofloxacin. The peak concentration of NY-198 in the lungs and sera of guinea pigs with experimentally induced Legionella pneumonia was higher than that of ciprofloxacin after oral administration. The overall survival rate was higher in animals treated with NY-198 than in those treated with ciprofloxacin. Thus, NY-198 appears valuable in the treatment of Legionnaires disease.
Kohno
S
S
Second Department of Internal Medicine, School of Medicine, Nagasaki University, Japan.
Yamaguchi
K
K
Dohtsu
Y
Y
Koga
H
H
Hayashi
T
T
Hirota
M
M
Saito
A
A
Hara
K
K
D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use; D024841:Fluoroquinolones; D006168:Guinea Pigs; D007877:Legionnaires' Disease / Q000188:drug therapy*; D008297:Male; D015363:Quinolones; D014018:Tissue Distribution
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; C053091:lomefloxacin